Table 4.

Anti-oxLDL antibodies and cardiac endpoints in subjects undergoing clinically indicated coronary angiography (CAG).

Author	Index Group (n)	Reference Group (n)	Follow-up Period, Years	Statistical Method	Matching Variables	Confounders Adjusted for in Statistical Analysis	Outcome	IgG Anti-oxLDL	IgM Anti-oxLDL
Maiolino [15]	CAG patients from highest IgG anti-MDA-LDL quartile (136)	CAG patients from the lower three IgG anti-MDA-LDL quartiles matched based on propensity score	7.2 (median)	Kaplan-Meier	Gender, Age, BMI, LDL- and HDL-cholesterol, triglycerides, serum creatinine, homocysteine, glycemia, serum sodium concentration, heart rate arterial hypertension, smoking habit, LVEF, the Duke Prognostic Index of coronary athersosclerotic burden, length of follow-up, history and treatment variables		Cardiac death, composite of non-fatal MI, non-fatal stroke, and cardiac death	Event-free survival; 1-3rd Q vs. 4th Q: 77.7% vs. 69.2%
Meeuwsen [16]	Carotid endarterectomy patients (168)		3	Cox regression			Composite of cardiac death, stroke, non-fatal MI, coronary intervention, and peripheral intervention (including amputation)	HR 1.01 (0.98–1.03)
Tsimikas [18]	CAG patients (504)		4 (median)	NR			Composite of non-fatal MI, non-fatal stroke, and cardiac death	NS	NS

↑ Indicates a significantly higher level in the index group compared with the reference group, ↓ Indicates a significantly higher level in the index group compared with the reference group. BMI: body mass index, CAG: coronary angiography, HDL: high density lipoprotein, Ig: immunoglobulin, LDL: low density lipoprotein, LVEF: left ventricular ejection fraction, NR: not reported, NS: not significant, MDA: malondiadehyde, MI: myocardial infarction, oxLDL: oxidized LDL.